Not yet recruiting
Breakthrough Platform Trial for PCAS
NCT07769086· Kagawa University· Source
Contact: Toru Takiguchi
Recruiting
Pemafibrate for Symptomatic ICAS RCT
NCT07562178· Tokyo Women's Medical University· Source
Contact: Satoshi Suda
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298· Phase 1/2· Pfizer· Source
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· Phase 3· Pfizer· Source
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997· Phase 3· ArriVent BioPharma, Inc.· Source
Contact: Clinical Trials
Recruiting
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229· Phase 3· Bristol-Myers Squibb· Source
Contact: Amane Tateno, Site 1305
Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146· Phase 3· Zai Lab (Shanghai) Co., Ltd.· Source
Recruiting
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT07213674· Phase 3· Amgen· Source
Active, not recruiting
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
NCT07108283· Phase 2· Takeda· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
NCT07140913· Phase 3· Bristol-Myers Squibb· Source
Contact: Amane Tateno, Site 0139
Recruiting
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· Phase 3· Pfizer· Source
Recruiting
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154· Phase 2· Astellas Pharma Global Development, Inc.· Source
Contact: Astellas Pharma Global Development, Inc.
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401· Phase 3· Pfizer· Source
Recruiting
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
NCT06929273· Phase 3· Bristol-Myers Squibb· Source
Contact: Amane Tateno, Site 0164
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
NCT07011732· Phase 3· Bristol-Myers Squibb· Source
Contact: Amane Tateno, Site 1305
Active, not recruiting
A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT07023341· Phase 3· Bayer· Source
Recruiting
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
NCT06698796· Phase 3· Pfizer· Source
Active, not recruiting
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT06691984· Phase 3· Amgen· Source
Recruiting
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649· Phase 3· Amgen· Source
Active, not recruiting
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575· Phase 3· Pfizer· Source
Active, not recruiting
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
NCT06163326· Phase 3· Pfizer· Source
Recruiting
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
NCT05895786· Phase 3· Pfizer· Source
Active, not recruiting
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416· Phase 3· Pfizer· Source
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555· Phase 1/2· Sumitomo Pharma America, Inc.· Source
Contact: Hiroki Yamaguchi, MD
Active, not recruiting
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
NCT04227847· Phase 1· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
NCT02960022· Phase 2· Astellas Pharma Global Development, Inc.· Source
Recruiting
Phase III Trial of Stage I Ovarian Cancer After Surgery
NCT04063527· Phase 3· Japanese Gynecologic Oncology Group· Source
Contact: Keisuke Kurose